Drugs /

parsaclisib

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3K) with potential antineoplastic activity. PI3K-delta inhibitor INCB050465 inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic disease and cell lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.

Clinical Trials

View Clinical Trials for parsaclisib

Parsaclisib has been investigated in 19 clinical trials, of which 17 are open and 2 are closed. Of the trials investigating parsaclisib, 10 are phase 1 (8 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), and 4 are phase 3 (4 open).

KMT2A Fusion, KMT2A-AFF1 Fusion, and KMT2A-ELL Fusion are the most frequent biomarker inclusion criteria for parsaclisib clinical trials.

Diffuse large B-cell lymphoma, myelofibrosis transformation in essential thrombocythemia, and polycythemia vera, post-polycythemic myelofibrosis phase are the most common diseases being investigated in parsaclisib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Parsaclisib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Parsaclisib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating parsaclisib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
pi3k-delta inhibitor incb050465, incb050465, pi3k-delta inhibitor incb050465
Drug Categories [2]:
PI3K inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
PIK3CD
NCIT ID [1]:
C113434

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.